aqua
aqua
Angie You Testimonial Headshot
Frank Watanabe Headshot
Krish Krishnan Headshot
Stephen Dilly Headshot

Investing in Transformational Therapeutics

View Portfolio
Working with Frazier when times were tough in a prior company gave me insight into their character and high integrity. Not only are they smart, low ego and not afraid to think big, they genuinely care about supporting their CEOs and companies.

Angie You

CEO
amunix logo
The Frazier team really distinguish themselves by being true partners to their companies. They have supported us every step of the way with resources, guidance and expertise as we built the company.

Frank Watanabe

Founder & CEO
arcutis logo
Frazier has been a long-standing partner to Krystal since our IPO in 2017. They are a firm of intellect and integrity, and I truly value their support as we evolved from an idea into a fully integrated biotechnology company.

Krish Krishnan

Chairman & CEO
krystal logo
I thoroughly enjoy working with the Frazier team both as investors and as a critical sounding board for new ideas. They are approachable and responsive and bring a well-informed, balanced view of opportunities and risks. Frazier partners particularly well with management teams by taking a patient and pragmatic view of the path to value creation.

Stephen Dilly

CEO
sierra oncology logo
yellow

Who We Are

Frazier Life Sciences is a healthcare investment firm focusing on companies developing novel therapeutics. We have two core funds that enable investments across all stages of therapeutics companies:

Venture Funds

Our Venture Funds primarily invest in private companies, focusing on company creation (over 30 companies formed since 2005) and Series A & B companies. We form true partnerships with distinctive entrepreneurs to build highly valuable companies and accelerate advancement of new therapeutic options for patients. Our latest Venture Fund is Frazier Life Sciences XI, a $987 million fund that was raised in 2022.

Public Funds

Our Public Funds provide capital to small- and mid-cap public biotech companies in financings, including follow-ons including CMPOs, PIPEs, IPOs, as well as supporting our companies in the open market. We partner with our public portfolio companies much as we do with our private portfolio companies. The Public Funds are investing over $1 billion of committed capital.

Newsroom

View All
Portfolio News
Apr 30, 2024
Enlaza Therapeutics Raises $100 Million through Its Series A...

Enlaza Therapeutics Raises $100 Million through Its Series A…

Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led…

link
Portfolio News
Jun 14, 2024
Disc Medicine Announces Underwritten Offering of Common Stock

Disc Medicine Announces Underwritten Offering of Common Stock

Disc Medicine Announces Underwritten Offering of Common Stock

link
Portfolio News
Apr 10, 2024
Diagonal Therapeutics Launches with $128 Million in Financing to...

Diagonal Therapeutics Launches with $128 Million in Financing to…

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a…

link
Portfolio News
Mar 14, 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical...

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical…

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical…

link

Drug Approvals

Our goal is to invest in therapeutics that ultimately benefit patients, and our portfolio has generated over 40 FDA approved therapeutics since 2010. Examples include:

vyjuvek logo

Krystal Biotech

calquence logo

Acerta Pharma

zoryve logo

Arcutis Biotherapeutics

livmarli logo

Mirum Pharmaceuticals

voquezna dual logo

Phathom Pharmaceuticals

jemperli logo

AnaptysBio

rozlytrek logo

Ignyta

xacduro logo

Entasis Therapeutics

xatmep logo

Silvergate Pharmaceuticals

zydelig logo

Calistoga Pharmaceuticals

Certain statements about Frazier Life Sciences made by portfolio company executives herein are intended to illustrate the work of Frazier’s team with such portfolio companies. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities, Senior Advisors, and/or investors in Frazier-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.

times icon menu bg caret up